Based on the roles that REV-ERBs play in regulating both metabolism and inflammation, it is possible that targeting REV-ERBs to suppress lipogenesis and/or inflammatory pathways, that include NLRP3 and NF-κB, with selective agonists may be beneficial and provide therapeutic utility for the treatment of NAFLD. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.